HC Wainwright Has Optimistic Outlook of Ocugen Q1 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Investment analysts at HC Wainwright lifted their Q1 2026 earnings estimates for shares of Ocugen in a research note issued to investors on Monday, March 9th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.06) per share for the quarter, up from their prior forecast of ($0.07). The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at ($0.10) EPS and FY2029 earnings at $0.26 EPS.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The firm had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.86 million.

A number of other research analysts also recently weighed in on OCGN. Weiss Ratings restated a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a report on Thursday, March 5th. Oppenheimer started coverage on shares of Ocugen in a research report on Wednesday. They issued an “outperform” rating and a $10.00 price objective on the stock. Finally, Wall Street Zen cut shares of Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Ocugen Stock Performance

Shares of OCGN opened at $2.30 on Wednesday. The stock has a market capitalization of $754.16 million, a price-to-earnings ratio of -10.00 and a beta of 2.75. The firm has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $1.45. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 8.04. Ocugen has a 12 month low of $0.52 and a 12 month high of $2.37.

Hedge Funds Weigh In On Ocugen

A number of hedge funds have recently bought and sold shares of OCGN. SmartHarvest Portfolios LLC acquired a new stake in shares of Ocugen in the fourth quarter valued at approximately $31,000. Schonfeld Strategic Advisors LLC acquired a new stake in Ocugen during the fourth quarter worth approximately $38,000. Verdence Capital Advisors LLC bought a new position in Ocugen during the 3rd quarter worth $47,000. Cora Capital Advisors LLC increased its stake in Ocugen by 27.5% during the 4th quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock worth $41,000 after acquiring an additional 6,500 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Ocugen by 28,222.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock valued at $41,000 after acquiring an additional 30,198 shares in the last quarter. 10.27% of the stock is owned by institutional investors.

Trending Headlines about Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Oppenheimer initiated coverage at “Outperform” with a $10 price target (implies ~334% upside vs. current levels), bringing fresh institutional attention and a large bullish valuation anchor for the stock. Oppenheimer Starts Ocugen at Outperform
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates for multiple 2026 quarters and lifted FY2026 forecasts slightly, signaling improving analyst outlook on near-term performance and clinical progress. HC Wainwright estimate updates
• Positive Sentiment: Ocugen completed enrollment for its Phase 3 OCU400 gene‑therapy trial — a major clinical milestone that derisks the program timeline and supports future value if readouts are positive. Phase 3 enrollment complete
• Positive Sentiment: Unusually large call buying (≈5,566 calls, ~62% above typical call volume) suggests speculative or directional bullish positioning from options traders, which can amplify upside moves in the underlying stock.
• Neutral Sentiment: Press coverage summarized 2025 results and clinical progress across Ocugen’s gene‑therapy pipeline — useful for context but not a single clear price catalyst. 2025 results & pipeline update
• Neutral Sentiment: Sector comparison pieces mention Ocugen alongside peers; these can influence sentiment but are not primary drivers of today’s move. Peer performance comparison
• Negative Sentiment: HC Wainwright trimmed several longer‑term EPS forecasts (FY2027–FY2029 and FY2028), reducing some future profitability expectations and highlighting execution/visibility risk beyond 2026. HC Wainwright long‑term estimate cuts

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.